Endogenous Fe²⁺-triggered self-targeting nanomicelles for self-amplifying intracellular oxidative stress

Abstract

Background: Artesunate (ASA) acts as an •O₂⁻ source through the breakdown of endoperoxide bridges catalyzed by Fe²⁺, yet its efficacy in ASA-based nanodrugs is limited by poor intracellular delivery.

Methods: ASA-hyaluronic acid (HA) conjugates were formed from hydrophobic ASA and hydrophilic HA by an esterification reaction first, and then self-targeting nanomicelles (NM) were developed using the fact that the amphiphilic conjugates of ASA and HA are capable of self-assembling in aqueous environments.

Results: These ASA-HA NMs utilize CD44 receptor-mediated transcytosis to greatly enhance uptake by breast cancer cells. Subsequently, endogenous Fe²⁺ from the tumor catalyzes the released ASA to produce highly toxic •O₂⁻ radicals to kill tumor cells, although sustained tumor growth inhibition can be achieved via in vivo experiments.

Conclusions: Self-targeting NMs represent a promising strategy for enhancing ASA-based treatments, leveraging clinically approved drugs to expedite drug development and clinical research in oncology.

Keywords

nanomicelles / non-Fenton / oxidative stress / reactive oxygen species / self-targeting

References

[1] Wang Z, Zhang Y, Ju E, et al. Biomimetic nanoflowers by self-assembly of nanozymes to induce intracellular oxidative damage against hypoxic tumors. Nat Commun. 2018;9(1):3334.

[2] Wu Y, Li Y, Lv G, Bu W. Redox dyshomeostasis strategy for tumor therapy based on nanomaterials chemistry. Chem Sci. 2022;13(8):2202-2217.

[3] Yu X, Zhang Y-C, Yang X, et al. Bonsai-inspired AIE nanohybrid photosensitizer based on vermiculite nanosheets for ferroptosis-assisted oxygen self-sufficient photodynamic cancer therapy. Nano Today. 2022;44:101477.

[4] Liang S, Yao J, Liu D, Rao L, Chen X, Wang Z. Harnessing nanomaterials for cancer sonodynamic immunotherapy. Adv Mater. 2023;35(33):2211130.

[5] Du Z, Wang X, Zhang X, et al. X-ray-triggered carbon monoxide and manganese dioxide generation based on scintillating nanoparticles for cascade cancer radiosensitization. Angew Chem Int Ed. 2023;62(23):e202302525.

[6] Xie W, Guo Z, Zhao L, Wei Y. The copper age in cancer treatment: from copper metabolism to cuproptosis. Prog Mater Sci. 2023;138:101145.

[7] Pan P, Dong X, Chen Y, Ye J-J, Sun Y-X, Zhang X-Z. A heterogenic membrane-based biomimetic hybrid nanoplatform for combining radiotherapy and immunotherapy against breast cancer. Biomaterials. 2022;289:121810.

[8] Li Y, Zhao P, Gong T, et al. Redox dyshomeostasis strategy for hypoxic tumor therapy based on DNAzyme-loaded electrophilic ZIFs. Angew Chem Int Ed. 2020;59(50):22537-22543.

[9] Li X, Zhou Q, Japir AA-WMM, Dutta D, Lu N, Ge Z. Protein-delivering nanocomplexes with Fenton reaction-triggered cargo release to boost cancer immunotherapy. ACS Nano. 2022;16(9):14982-14999.

[10] Li Q, Yu J, Lin L, et al. One-pot rapid synthesis of Cu²⁺-doped GOD@MOF to amplify the antitumor efficacy of chemodynamic therapy. ACS Appl Mater Interfaces. 2023;15(13):16482-16491.

[11] Xiang S, Fan Z, Ye Z, et al. Endogenous Fe²⁺−activated ROS nanoamplifier for esterase-responsive and photoacoustic imaging-monitored therapeutic improvement. Nano Res. 2022;15(2):907-918.

[12] Wang S, Yu K, Yu Z, et al. Targeting self-enhanced ROS-responsive artesunatum prodrug nanoassembly potentiates gemcitabine activity by down-regulating CDA expression in cervical cancer. Chin Chem Lett. 2023;34(7):108184.

[13] Fan Z, Jiang B, Zhu Q, et al. Tumor-specific endogenous FeII-activated, MRI-guided self-targeting gadolinium-coordinated theranostic nanoplatforms for amplification of ROS and enhanced chemodynamic chemotherapy. ACS Appl Mater Interfaces. 2020;12(13):14884-14904.

[14] Ismail M, Yang W, Li Y, et al. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. Biomaterials. 2022;287:121608.

[15] Wang D, He IW, Liu J, et al. Missing-linker-assisted artesunate delivery by metal–organic frameworks for synergistic cancer treatment. Angew Chem Int Ed. 2021;60(50):26254-26259.

[16] Gao Y, Zhang H, Tang L, et al. Cancer nanobombs delivering artoxplatin with a polyigniter bearing hydrophobic ferrocene units upregulate PD-L1 expression and stimulate stronger anticancer immunity. Adv Sci. 2024;11:e2300806.

[17] Xiao X, Wang Y, Chen J, et al. Self-targeting platinum(IV) amphiphilic prodrug nano-assembly as radiosensitizer for synergistic and safe chemoradiotherapy of hepatocellular carcinoma. Biomaterials. 2022;289:121793.

[18] Fan Z, Shi D, Zuo W, et al. Trojan-horse diameter-reducible nanotheranostics for macroscopic/microscopic imaging-monitored chemo-antiangiogenic therapy. ACS Appl Mater Interfaces. 2022;14(4):5033-5052.

[19] Bhattacharyya M, Jariyal H, Srivastava A. Hyaluronic acid: more than a carrier, having an overpowering extracellular and intracellular impact on cancer. Carbohydr Polym. 2023;317:121081.

[20] Ming J, Zhu T, Yang W, et al. Pd@Pt-GOx/HA as a novel enzymatic cascade nanoreactor for high-efficiency starving-enhanced chemodynamic cancer therapy. ACS Appl Mater Interfaces. 2020;12(46):51249-51262.

[21] Nakka K, Hachmer S, Mokhtari Z, et al. JMJD3 activated hyaluronan synthesis drives muscle regeneration in an inflammatory environment. Science. 2022;377(6606):666-669.

[22] Liu J, Smith S, Wang C. Photothermal attenuation of cancer cell stemness, chemoresistance, and migration using CD44-targeted MoS2 nanosheets. Nano Lett. 2023;23(5):1989-1999.

[23] Fan Z, Jiang B, Shi D, et al. Selective antitumor activity of drug-free TPGS nanomicelles with ROS-induced mitochondrial cell death. Int J Pharm. 2021;594:120184.

[24] Fan Z, Jin H, Tan X, et al. ROS-responsive hierarchical targeting vehicle-free nanodrugs for three-pronged Parkinson’s disease therapy. Chem Eng J. 2023;466:143245.

[25] Huang P, Wang D, Su Y, et al. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. J Am Chem Soc. 2014;136(33):11748-11756.

[26] Xia X, Yang X, Huang P, Yan D. ROS-responsive nanoparticles formed from RGD–epothilone B conjugate for targeted cancer therapy. ACS Appl Mater Interfaces. 2020;12(16):18301-18308.

[27] Li Y, Zhang H, Chen Y, et al. Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug–drug conjugate for synergistic targeted delivery and combinational tumor therapy. Biomater Sci. 2018;6(7):1818-1833.

[28] Fan Z, Wang Y, Xiang S, et al. Dual-self-recognizing, stimulus-responsive and carrier-free methotrexate–mannose conjugate nanoparticles with highly synergistic chemotherapeutic effects. J Mater Chem B. 2020;8(9):1922-1934.

[29] Fan W, Xiang J, Wei Q, et al. Role of micelle size in cell transcytosis-based tumor extravasation, infiltration, and treatment efficacy. Nano Lett. 2023;23(9):3904-3912.

[30] Ding Y, Hu X, Piao Y, et al. Lipid prodrug nanoassemblies via dynamic covalent Boronates. ACS Nano. 2023;17(7):6601-6614.

[31] Wu Q, Hu Y, Yu B, Hu H, Xu F-J. Polysaccharide-based tumor microenvironment-responsive drug delivery systems for cancer therapy. J Control Release. 2023;362:19-43.

[32] Huang L, Zhao S, Fang F, Xu T, Lan M, Zhang J. Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy. Biomaterials. 2021;268:120557.

[33] Behzadi S, Serpooshan V, Tao W, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev. 2017;46(14):4218-4244.

[34] Zhang H, Chen W, Wang J, et al. A novel ROS-activable self-immolative prodrug for tumor-specific amplification of oxidative stress and enhancing chemotherapy of mitoxantrone. Biomaterials. 2023;293:121954.

[35] Xu Y, Liu R, Li R, et al. Manipulating neovasculature-targeting capability of biomimetic nanodiscs for synergistic photoactivatable tumor infarction and chemotherapy. ACS Nano. 2023;17(16):16192-16203.

[36] Shi D, Wu F, Huang L, et al. Bioengineered nanogenerator with sustainable reactive oxygen species storm for self-reinforcing sono-chemodynamic oncotherapy. J Colloid Interface Sci. 2023;646:649-662.

[37] Wang S, Shi H, Wang L, et al. Photostable small-molecule NIR-II fluorescent scaffolds that cross the blood–brain barrier for noninvasive brain imaging. J Am Chem Soc. 2022;144(51):23668-23676.

[38] Singh N, Kim J, Kim J, et al. Covalent organic framework nanomedicines: biocompatibility for advanced nanocarriers and cancer theranostics applications. Bioact Mater. 2023;21:358-380.

RIGHTS & PERMISSIONS

2024 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.